Pathophysiology, Genetics & Classification

Question	Answer
1. What is the fundamental immunopathological mechanism driving pediatric Immune Thrombocytopenia (ITP)?	1. Loss of peripheral immune tolerance to platelet-specific autoantigens. 2. Production of autoreactive antibodies (predominantly IgG) targeting platelet surface glycoproteins. 3. Accelerated antibody-mediated clearance of opsonized platelets in the reticuloendothelial system.
2. Which platelet membrane glycoproteins are most commonly targeted by autoantibodies in ITP?	1. Glycoprotein IIb/IIIa (integrin alpha-IIb/beta-3). 2. Glycoprotein Ib/IX complex. 3. Autoantibodies directed against these structures induce both splenic phagocytosis and impaired megakaryocyte proplatelet formation.
3. How does cellular immunity contribute to the pathophysiology of ITP alongside humoral mechanisms?	1. T-cell dysregulation characterized by a skewed Th1 and Th17 response with defective regulatory T-cell (Treg) function. 2. Cytotoxic T-lymphocyte-mediated destruction of platelets and direct suppression of bone marrow megakaryopoiesis.
4. Why is platelet production paradoxically reduced or inadequate in classic ITP?	1. Autoantibodies and inflammatory cytokines (e.g., IL-6, IFN-gamma) inhibit bone marrow megakaryocyte maturation and proplatelet shedding. 2. Relative or absolute deficiency of thrombopoietin (TPO) relative to the degree of peripheral thrombocytopenia.
5. What is the primary anatomical site responsible for the clearance of antibody-coated platelets?	1. The spleen serves as the primary site of destruction, housing resident macrophages that express high-affinity Fc gamma receptors. 2. Secondary clearance occurs within hepatic sinusoids by Kupffer cells when splenic capacity is saturated or post-splenectomy.
6. How does an antecedent viral prodrome trigger the loss of immune tolerance in acute childhood ITP?	1. Molecular mimicry between viral epitopes and platelet membrane glycoproteins. 2. Bystander activation of dormant autoreactive clones during a robust antiviral immune response (e.g., following URTI, varicella, or MMR vaccination).
7. What are the key criteria defining Newly Diagnosed ITP according to international consensus guidelines?	1. Any case of ITP within 3 months of initial presentation. 2. This stage encompasses the vast majority of pediatric patients who experience spontaneous or treatment-induced complete remission.
8. How is Persistent ITP clinically differentiated from Newly Diagnosed and Chronic ITP?	1. Persistent ITP spans the time window between 3 and 12 months following initial diagnosis. 2. Patients in this phase have neither spontaneously remitted nor met the 1-year threshold required for chronic categorization.
9. What duration of thrombocytopenia classifies pediatric ITP as Chronic ITP?	1. Thrombocytopenia lasting continuously for 12 months or longer from the date of initial diagnosis. 2. Chronic ITP is significantly less common in children compared to adults, occurring in only 10% to 20% of pediatric cohorts.
10. How is the severity of ITP graded clinically based on bleeding manifestations?	1. Mild ITP: Skin manifestations only (petechiae and ecchymoses, dry purpura) with no significant bleeding. 2. Moderate ITP: More severe skin bleeding or mild mucosal bleeding. 3. Severe ITP: Presence of bleeding symptoms requiring systemic therapy or any life-threatening hemorrhage.
11. What is the precise operational definition distinguishing 'Dry Purpura' from 'Wet Purpura'?	1. Dry purpura refers strictly to cutaneous findings (petechiae, purpura, and ecchymoses) without mucosal involvement. 2. Wet purpura denotes active mucosal bleeding, including epistaxis, gingival bleeding, melena, menorrhagia, or hematuria, which warrants aggressive pharmacological intervention.
12. What genetic syndromes should be suspected when a child presents with congenital or inherited thrombocytopenia mimicking ITP?	1. Wiskott-Aldrich syndrome (WAS gene mutations, small platelets, eczema). 2. Bernard-Soulier syndrome (giant platelets). 3. May-Hegglin anomaly and MYH9-related disorders. 4. TAR syndrome (absent radii with normal ulnae).
13. How does the pathophysiology of Primary ITP differ fundamentally from Secondary ITP?	1. Primary ITP is an autoimmune disorder occurring in the absence of any identifiable underlying systemic trigger or disease. 2. Secondary ITP arises secondary to established conditions such as systemic lupus erythematosus, common variable immunodeficiency, autoimmune lymphoproliferative syndrome (ALPS), or chronic infections (HIV, HCV).
14. VIVA TRAP: Can primary pediatric ITP be classified as a purely antibody-mediated disease of accelerated peripheral destruction?	NO. While accelerated splenic clearance via anti-platelet IgG is the classic hallmark, impaired central and peripheral megakaryopoiesis and cellular immune dysregulation (T-cell-mediated cytotoxicity) play equally vital roles in its pathophysiology.
15. What role do Fc gamma receptors play on splenic macrophages in the pathogenesis of ITP?	1. Splenic macrophage Fc gamma receptors (specifically Fc gamma RI, RIIA, and RIIIa) bind the Fc portion of anti-platelet autoantibodies coating circulating platelets. 2. This triggers receptor-mediated phagocytosis and subsequent destruction of the opsonized platelets.
16. Why is serum thrombopoietin (TPO) levels characteristically normal or only mildly elevated in ITP despite profound thrombocytopenia?	1. TPO is constitutively produced by the liver and primarily cleared by binding to circulating platelets via the c-Mpl receptor. 2. In thrombocytopenia, decreased platelet mass leads to less TPO clearance, yet bone marrow megakaryocyte mass fails to upregulate TPO production adequately due to local cytokine-mediated suppression.
17. What distinguishes benign incidental thrombocytopenia of childhood from true autoimmune ITP?	1. Incidental thrombocytopenia is an asymptomatic, isolated, mild-to-moderate finding discovered on routine complete blood counts. 2. It lacks autoantibody-mediated destruction, exhibits stable platelet counts over time, and requires no therapeutic intervention or extensive bone marrow workup.
18. How do regulatory T-cells (Tregs) influence the natural history of acute versus chronic pediatric ITP?	1. Transient functional suppression or depletion of Tregs occurs during acute viral-triggered ITP, resolving with viral clearance. 2. Persistent functional impairment and numerical reduction of Tregs are strongly associated with progression to chronic, treatment-refractory ITP.
19. What defines Refractory ITP in pediatric practice?	1. Failure to achieve a response or subsequent relapse after second-line therapies (such as rituximab, splenectomy, or thrombopoietin receptor agonists). 2. Requires a rigorous reassessment of the initial diagnosis to rule out alternative bone marrow failure syndromes or inherited thrombocytopenias.
20. VIVA TRAP: Does a positive anti-platelet antibody assay confirm the diagnosis of pediatric ITP?	NO. Anti-platelet antibody assays (such as MAIPA) lack sufficient sensitivity and specificity in children; ITP remains primarily a clinical diagnosis of exclusion after ruling out other secondary causes of isolated thrombocytopenia.

Clinical History & Bedside Evaluation

Question	Answer
1. What is the classic age of onset peak for typical acute post-viral Immune Thrombocytopenia in children?	Typical acute childhood ITP peaks between 2 and 6 years of age, with equal distribution among males and females.
2. What temporal relationship between an antecedent infection and the appearance of cutaneous purpura is classically elicited in ITP?	A lag period of 1 to 4 weeks is typically noted between an uncomplicated upper respiratory tract infection, viral exanthem, or gastroenteritis and the onset of bruising.
3. Which specific vaccination history within the preceding 4 to 6 weeks must be actively sought during the clinical timeline review?	History of administration of live-attenuated viral vaccines, particularly Measles, Mumps, and Rubella (MMR) or Varicella, as they can trigger transient immune thrombocytopenia.
4. How does the onset profile of petechiae and ecchymoses in ITP contrast with the history obtained in coagulation defects like hemophilia?	ITP characteristically presents with an acute, abrupt onset of superficial skin and mucosal bleeding, whereas coagulation disorders present with delayed, deep tissue bleeding following trauma.
5. What dietary recall questions are crucial in a toddler presenting with acute petechiae to rule out nutritional or toxic mimics?	Detailed inquiry regarding ingestion of unpasteurized cow milk (associated with HUS), heavy metal exposure (lead), or recent macrocytic dietary restrictions causing severe folate or B12 deficiency.
6. Why is a thorough perinatal and neonatal history mandatory when evaluating an infant presenting with isolated thrombocytopenia?	To rule out neonatal alloimmune thrombocytopenia (NAIT), congenital infections (TORCH), maternal autoimmune disorders like systemic lupus erythematosus, or inherited bone marrow failure syndromes.
7. What specific developmental and milestone history helps distinguish acquired ITP from inherited bone marrow failure syndromes like Fanconi anemia?	Inherited syndromes often feature delayed growth, microcephaly, thumb or radial ray anomalies, and delayed developmental milestones, whereas children with ITP are typically well-nourished and developmentally normal.
8. What specific elements must be probed when taking a family pedigree in a child suspected of having ITP?	History of recurrent bruising, bleeding tendencies, early-onset autoimmune diseases, consanguinity, or unexplained neonatal deaths suggesting inherited thrombocytopenias like Wiskott-Aldrich syndrome or MYH9-related disorders.
9. What constitutional red flag symptoms in the history immediately direct the examiner away from a diagnosis of isolated ITP?	Presence of prolonged unexplained fever, persistent severe bone or joint pain waking the child from sleep, significant anorexia, and rapid weight loss strongly suggest acute leukemia or marrow infiltration.
10. How does the anatomical distribution of lymphadenopathy and organomegaly in the clinical history differentiate ITP from leukemia?	Classic ITP presents with a complete absence of generalized lymphadenopathy and hepatosplenomegaly; their presence points toward malignant, infiltrative, or storage disorders.
11. What nocturnal symptom history is especially valuable in ruling out pediatric malignancies during the bedside evaluation?	Bone pain that is severe enough to wake the child from sleep or prevents weight-bearing is a classic red flag for acute lymphoblastic leukemia rather than benign ITP.
12. What specific features in the bleeding history differentiate 'dry purpura' from 'wet purpura' at the bedside?	Dry purpura consists exclusively of skin petechiae and ecchymoses, whereas wet purpura involves active mucosal bleeding such as epistaxis, gingival bleeding, melena, or gross hematuria.
13. What historical clue regarding the child's general activity level and well-being is a hallmark of uncomplicated acute ITP?	Parents almost universally report that despite widespread petechiae and bruising, the child remains surprisingly active, playful, and completely systemically well.
14. What physical finding during a bedside abdominal examination must be documented to firmly exclude hypersplenism or infiltrative disease?	Palpation of the abdomen to confirm a completely soft, non-tender abdomen with a non-palpable liver and spleen, as splenomegaly is uncharacteristic of primary ITP.
15. VIVA TRAP: Can a history of recurrent minor epistaxis lasting a few seconds in an otherwise asymptomatic child confirm a diagnosis of chronic ITP?	NO. Brief, isolated, minor anterior epistaxis is common in healthy children and does not reliably indicate pathological bleeding or chronic ITP without objective documentation of thrombocytopenia and systemic bleeding scores.
16. What specific bleeding sites in the clinical history mandate immediate emergency intervention regardless of the platelet count?	History of visual disturbances, severe unrelenting headache, altered sensorium, or focal neurological deficits suggesting intracranial hemorrhage.
17. VIVA TRAP: Does a history of recurrent petechiae following minor trauma in a toddler always point toward an autoimmune process like ITP?	NEVER. It can also point toward non-accidental injury (child abuse), congenital bleeding disorders, vascular malformations, or non-immune consumptive coagulopathies like DIC.
18. What specific items must be actively probed during the clinical history to identify an antecedent viral prodrome or potential vaccine exposure in a child presenting with newly suspected immune thrombocytopenia?	1. Specifically inquire about upper respiratory tract infections, gastroenteritis, or exanthemal illnesses occurring 1 to 4 weeks prior to the onset of petechiae. 2. Explicitly ask about recent live-attenuated vaccinations, particularly the MMR vaccine, given its established association with transient post-immunization immune thrombocytopenia.

Physical Examination & Bedside Signs

Question	Answer
1. What is the single most crucial physical examination finding that defines uncomplicated 'Dry Purpura' in ITP?	Presence of scattered petechiae, purpura, and ecchymoses strictly confined to the skin without any evidence of mucosal involvement.
2. How is 'Wet Purpura' clinically identified during inspection of the oral cavity and mucous membranes?	Inspection reveals active or recent mucosal bleeding manifestations such as hemorrhagic bullae on the buccal mucosa, gingival bleeding, or epistaxis.
3. What specific cutaneous lesions must the examiner actively look for to differentiate simple petechiae from non-blanching palpable purpura seen in vasculitis?	Palpable purpura with raised lesions indicates vascular inflammation, whereas classic ITP petechiae and ecchymoses are entirely flat and non-palpable.
4. How should the examiner systematically inspect the oral cavity for wet purpura severity?	Inspect the soft palate, buccal mucosa, and gums specifically for blood blisters (hemorrhagic bullae), which signify high-risk mucosal bleeding.
5. What specific systemic examination finding in the skeletal system must be documented to rule out congenital bone failure syndromes?	Assessment for absent or hypoplastic radii, thumb anomalies, or skeletal deformities characteristic of TAR syndrome or Fanconi anemia.
6. What detailed inspection of the skin, hair, and nails must be performed in a toddler with thrombocytopenia to exclude inherited marrow failure?	Inspection for café-au-lait spots, microcephaly, abnormal thumb ray development, or pigmentary abnormalities suggestive of Fanconi anemia.
7. Why is a meticulous general physical inspection for lymphadenopathy mandatory in every suspected ITP case?	Generalized lymphadenopathy is absent in primary ITP; its presence strongly points toward acute lymphoblastic leukemia, lymphoma, or infection.
8. What vital sign abnormality, if present during the initial physical examination, demands an immediate revision of the differential diagnosis away from isolated ITP?	Persistent or unexplained fever, which points toward systemic infection, sepsis, or a malignant process rather than uncomplicated ITP.
9. What neurological examination must be performed immediately if a child with ITP presents with lethargy, headache, or vomiting?	A focused neurological examination assessing for signs of intracranial hemorrhage, altered sensorium, or focal neurological deficits.
10. How does the systemic appearance and general well-being of a child with acute ITP typically present on initial observation?	The child appears remarkably well, active, and playful, completely out of proportion to the startling degree of cutaneous petechiae and purpura.
11. What specific ophthalmological sign should be actively sought during bedside examination in a patient presenting with severe wet purpura?	Retinal hemorrhages, which serve as a critical warning sign of impending or active intracranial hemorrhage requiring urgent intervention.
12. What bedside examination finding in a male infant with microthrombocytopenia and eczema clinches a diagnosis other than primary ITP?	Recurrent pyogenic infections and eczema, which together with thrombocytopenia define Wiskott-Aldrich syndrome.
13. What physical signs of hyper- or hypothyroidism must be screened for during the general inspection of an adolescent presenting with chronic thrombocytopenia?	Goiter, tremors, exophthalmos, or skin texture changes, as autoimmune thyroid disease can be associated with secondary ITP.
14. How should joint and extremity examinations be conducted at the bedside to differentiate ITP from hemophilia?	Palpation of large joints (knees, ankles) for hemarthrosis; joint swelling and restricted movement are characteristic of hemophilia but completely absent in ITP.
15. What specific inspection finding on the nails and palmar creases is sought when evaluating constitutional bone marrow failure mimics?	Inspection for hypoplastic thumbs, absent thenar eminences, or abnormal palmar creases seen in inherited thrombocytopenia syndromes.
16. VIVA TRAP: 18. VIVA TRAP: Can a palpable spleen tip of 1 cm below the left costal margin in a well-nourished 5-year-old child completely rule out a diagnosis of ITP?	NO. A barely palpable spleen tip can occasionally be felt in normal children, but significant, firm splenomegaly strongly excludes uncomplicated primary ITP.
17. VIVA TRAP: 20. VIVA TRAP: Does the presence of generalized petechiae covering the entire body necessitate immediate bone marrow aspiration during the initial physical examination?	NONE. The extent of cutaneous petechiae (dry purpura) does not dictate bone marrow examination; marrow aspiration is reserved for atypical features, treatment refractoriness, or pre-therapy staging if malignancy is suspected.
18. What specific physical examination findings must be systematically evaluated to differentiate primary immune thrombocytopenia (ITP) from secondary causes such as acute leukemia or infiltrative bone marrow disorders?	1. Palpate carefully for generalized lymphadenopathy and hepatosplenomegaly, which are characteristically absent in primary ITP and point toward malignancy or storage disorders. 2. Inspect the skin and mucous membranes to categorize the bleeding manifestations strictly into dry purpura (skin only) versus wet purpura (mucosal bleeding). 3. Examine the musculoskeletal and skeletal systems for localized bony tenderness, which strongly suggests leukemic infiltration rather than isolated immune-mediated thrombocytopenia.

Diagnostic Criteria & Investigations

Question	Answer
1. What is the gold standard diagnostic laboratory investigation required to establish a primary diagnosis of Immune Thrombocytopenia?	Isolated thrombocytopenia with a platelet count below 100,000/µL, combined with a completely normal peripheral blood smear and the absence of other cytopenias or systemic illnesses.
2. What specific morphological features on a peripheral blood smear are mandatory to confirm typical childhood ITP?	Normocytic normochromic red cells, normal white blood cell morphology without blasts or atypical cells, and the presence of occasional large platelets (megathrombocytes) reflecting adequate bone marrow regeneration.
3. What bone marrow examination finding is classically expected in a patient with uncomplicated ITP, and when is it indicated?	Increased or normal numbers of morphologically normal megakaryocytes; bone marrow aspiration is NOT routinely required for typical presentations and is reserved for atypical cases, pre-steroid therapy in refractory cases, or prior to splenectomy.
4. What specific baseline laboratory investigations must be ordered alongside a complete blood count when evaluating a new-onset case of pediatric thrombocytopenia?	Peripheral blood smear examination, reticulocyte count, and baseline coagulation profile (PT/INR and aPTT) to rule out disseminated intravascular coagulation or liver dysfunction.
5. What specific screening tests are mandated for adolescent females presenting with persistent or chronic thrombocytopenia before initiating immunosuppressive therapy?	Antinuclear antibody (ANA) testing and direct Coombs test (DAT) to rule out systemic lupus erythematosus and Evans syndrome.
6. Which viral serologies are routinely recommended as part of the initial secondary workup in endemic regions for children presenting with isolated thrombocytopenia?	Screening for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV), and Epstein-Barr Virus or Cytomegalovirus when clinical suspicion warrants.
7. What radiological imaging (such as an ultrasound abdomen) is useful when evaluating a child with suspected ITP?	Ultrasound is indicated only when hepatosplenomegaly is detected clinically, to assess organomegaly and rule out portal hypertension or infiltrative hypersplenism.
8. When is a chest radiograph or non-contrast head CT scan indicated in the initial diagnostic workup of pediatric ITP?	Chest X-ray is reserved for patients with suspected pulmonary hemorrhage or thymic/mediastinal pathology, while head CT is strictly indicated if acute intracranial hemorrhage is suspected due to severe neurological symptoms.
9. How does the peripheral blood smear differentiate ITP from Thrombotic Thrombocytopenic Purpura (TTP) or Hemolytic Uremic Syndrome (HUS)?	ITP lacks schistocytes (fragmented red blood cells) and microangiopathic hemolytic anemia, which are cardinal diagnostic features of TTP and HUS.
10. What diagnostic cutoff for hemoglobin and total leukocyte count must be maintained to ensure the thrombocytopenia is genuinely isolated in primary ITP?	Hemoglobin and total leukocyte count (with differential) must be strictly within age-adjusted normal reference ranges, with absolute absence of leukopenia, leukocytosis, or anemia (unless secondary to iron deficiency from acute bleeding).
11. What specific blood group testing must be performed promptly at the time of initial diagnostic evaluation in moderate-to-severe ITP?	Blood grouping and cross-matching (ABO and Rh typing) must be performed immediately in case emergency platelet transfusions or blood products are required for severe bleeding.
12. What immunoglobulin levels should be measured as part of an extended diagnostic evaluation in a child with recurrent or chronic ITP?	Serum quantitative immunoglobulins (IgG, IgA, IgM) to rule out underlying Common Variable Immunodeficiency (CVID) or selective IgA deficiency.
13. How does flow cytometry help in differentiating inherited thrombocytopenias from immune thrombocytopenia in young children?	Flow cytometry can detect specific surface glycoprotein deficiencies, such as GPIb/IX complex defects in Bernard-Soulier syndrome or GPIIb/IIIa in Glanzmann thrombasthenia.
14. VIVA TRAP: 18. VIVA TRAP: Is a bone marrow aspiration mandatory before starting oral corticosteroids in a typical 4-year-old child presenting with acute dry purpura and a platelet count of 15,000/µL?	NO. Bone marrow examination is completely unnecessary in a child with classic presentation, normal physical exam, and normal peripheral smear.
15. What specific diagnostic criteria categorize ITP as 'severe' according to international working group classifications?	Severe ITP is defined by the presence of bleeding symptoms sufficient to treat at initial presentation or the occurrence of new bleeding episodes requiring therapeutic intervention.
16. VIVA TRAP: 20. VIVA TRAP: Can a mildly positive ANA titer in a newly diagnosed 3-year-old toddler with isolated petechiae confirm a diagnosis of autoimmune lymphoproliferative syndrome (ALPS)?	NO. A low-titer positive ANA can be an incidental post-viral finding; diagnosing ALPS requires specialized flow cytometry for double-negative T cells, elevated serum vitamin B12, and Fas-mediated apoptosis assays.
17. What specific morphological abnormalities must be actively searched for on a peripheral blood smear to rule out inherited thrombocytopenias or myelodysplastic syndromes in a child evaluated for suspected ITP?	1. Giant platelets (approaching or exceeding the size of red blood cells) or leukocyte inclusion bodies pointing toward May-Hegglin anomaly or Epstein syndrome. 2. Pale, gray platelets with defective granulation suggesting storage pool disorders or Gray platelet syndrome. 3. Dysplastic changes, microcytic/macrocytic red cell indices, or circulating blasts which completely rule out primary ITP and indicate bone marrow failure or malignancy.
18. VIVA TRAP: Can diagnostic anti-platelet autoantibody assays (such as Direct Antiglobulin or MAIPA tests) be utilized as a mandatory confirmatory gold-standard test to secure a definitive diagnosis of immune thrombocytopenia in pediatric clinical practice?	NO. Anti-platelet antibody assays lack both adequate sensitivity (around 50-60%) and specificity, and international guidelines explicitly recommend against their routine clinical use because a negative test does not exclude ITP and a positive test can appear in other secondary thrombocytopenias.

Evidence-Based Management & Pharmacotherapy

Question	Answer
1. What is the primary management strategy recommended by international guidelines for children presenting with newly diagnosed ITP and mild skin-only manifestations (dry purpura), regardless of the platelet count?	1. Watchful waiting and observation without pharmacotherapy. 2. Regular clinical follow-up to monitor for the development of wet purpura or bleeding symptoms.
2. What is the standard oral corticosteroid dosing regimen and duration for treating a child with moderate-to-severe mucosal bleeding (wet purpura) secondary to ITP?	1. Prednisolone administered at 2 to 4 mg/kg/day (maximum 60 to 80 mg/day) for 4 to 7 days, followed by a rapid taper. 2. Alternatively, 2 mg/kg/day for 14 days.
3. What is the exact dosage and route of administration for Intravenous Immunoglobulin (IVIG) when rapid platelet recovery is required in acute symptomatic ITP?	1. 0.8 to 1.0 g/kg administered as a single intravenous infusion. 2. Can be repeated once if the platelet response is inadequate after 24 to 48 hours.
4. What is the emergency medical and surgical cocktail required for a child presenting with life-threatening intracranial hemorrhage due to severe ITP?	1. Immediate emergency platelet transfusion combined with high-dose IV methylprednisolone (30 mg/kg/day) and IVIG (1 g/kg). 2. Urgent neurosurgical consultation for consideration of surgical intervention.
5. What are the common acute side-effects associated with high-dose intravenous immunoglobulin infusions that the clinician must monitor for during administration?	1. Aseptic meningitis, severe headache, and fever. 2. Nausea, vomiting, and transient volume overload or acute renal impairment.
6. What specific monitoring parameters must be checked before and during the administration of IV Anti-D immunoglobulin?	1. Direct Coombs test and baseline hemoglobin levels. 2. Monitoring for delayed intravascular hemolysis, hemoglobinuria, and renal function.
7. What dietary or activity restrictions must be strictly enforced in a child diagnosed with acute ITP and a platelet count below 20,000/µL?	1. Avoidance of contact sports, rough play, and activities with high risk of head trauma. 2. Avoidance of non-steroidal anti-inflammatory drugs (NSAIDs) and aspirin, which impair platelet function.
8. What is the precise pharmacological mechanism of thrombopoietin receptor agonists (TPO-RAs) like Eltrombopag or Romiplostim in chronic ITP?	1. They bind to the transmembrane domain of the thrombopoietin receptor on megakaryocytes. 2. They stimulate intracellular signal transduction pathways that increase megakaryocyte proliferation and platelet production.
9. What mandatory baseline investigation and periodic monitoring must be performed for a patient initiated on Eltrombopag therapy?	1. Serum alanine transaminase (ALT), aspartate transaminase (AST), and total bilirubin levels. 2. Periodic monitoring for hepatotoxicity and regular ophthalmological screening for cataract formation.
10. What is the exact oral dosage and administration guideline for Eltrombopag when used in pediatric patients older than one year with chronic ITP?	1. Initial dose of 50 mg once daily for children aged 6 years and older (25 mg for children aged 1 to 5 years). 2. Must be taken on an empty stomach, avoiding calcium, iron, and dairy products 2 hours before or 4 hours after ingestion.
11. What second-line rituximab dosing regimen is commonly employed for pediatric chronic ITP refractory to first-line therapies?	1. 375 mg/m² body surface area administered as an intravenous infusion once weekly for four consecutive weeks.
12. What is the primary mechanism of action of Rituximab in the management of refractory chronic ITP?	1. Chimeric monoclonal antibody targeting the CD20 antigen on the surface of B lymphocytes. 2. Induces B-cell depletion, thereby reducing the production of anti-platelet autoantibodies by plasma cell precursors.
13. What are the absolute indications for performing a therapeutic splenectomy in children with chronic refractory ITP?	1. Life-threatening or recurrent severe bleeding refractory to all medical therapies (corticosteroids, IVIG, anti-D, TPO-RAs, rituximab) persisting for at least 12 months.
14. What mandatory pre-splenectomy vaccinations must be administered, and when should they be completed?	1. Pneumococcal (conjugate and polysaccharide), Meningococcal, and Haemophilus influenzae type b (Hib) vaccines. 2. Completed at least 2 weeks prior to elective surgical intervention.
15. What lifelong prophylactic antibiotic therapy is mandated following surgical splenectomy in pediatric patients to prevent overwhelming postsplenectomy infection (OPSI)?	1. Oral penicillin V prophylaxis (125 mg twice daily for children under 5 years, 250 mg twice daily for older children). 2. Continued at least until age 5 or for life depending on institutional guidelines.
16. VIVA TRAP: 18. VIVA TRAP: Can prophylactic platelet transfusions be routinely prescribed to keep the platelet count above 50,000/µL in an asymptomatic child with chronic stable ITP?	NEVER. Prophylactic platelet transfusions are ineffective in ITP due to immediate immune-mediated destruction of transfused platelets and are reserved strictly for life-threatening hemorrhages or emergency surgical hemostasis.
17. What specific long-term surveillance monitoring must be maintained for pediatric patients in sustained remission from chronic ITP?	1. Periodic complete blood counts to ensure stable platelet counts and exclude the emergence of bone marrow failure or autoimmune cytopenias like Evans syndrome.
18. VIVA TRAP: 20. VIVA TRAP: Should systemic corticosteroids be tapered over several weeks when treating an initial episode of acute ITP lasting less than 7 days?	NO. Short courses of high-dose corticosteroids (e.g., 4 to 7 days) can be abruptly stopped without tapering because the duration of therapy is too short to cause significant hypothalamic-pituitary-adrenal axis suppression.

High-Yield VIVA TRAPs & Examiner Pitfalls

Question	Answer
1. VIVA TRAP: Can a single routine platelet count of 8,000/µL in an otherwise asymptomatic child with dry purpura justify immediate admission and emergency intravenous immunoglobulin administration?	NO. Asymptomatic children with dry purpura, regardless of an extremely low platelet count, do not require emergency admission or intervention; international guidelines firmly recommend a watchful waiting (observation) strategy.
2. VIVA TRAP: Is routine administration of packed red blood cells or prophylactic platelet transfusions indicated for a stable child with newly diagnosed acute ITP and a platelet count of 10,000/µL?	NEVER. Prophylactic transfusions are ineffective in ITP because infused platelets are rapidly destroyed by circulating anti-platelet antibodies; they are strictly reserved for life-threatening hemorrhages.
3. VIVA TRAP: Should Intravenous Immunoglobulin (IVIG) be administered at standard doses to a patient known to have selective IgA deficiency who presents with severe mucosal bleeding secondary to ITP?	NEVER. Administration of standard IVIG to an IgA-deficient patient precipitates severe, life-threatening anaphylactic reactions due to anti-IgA antibodies; alternative therapies like high-dose methylprednisolone must be utilized.
4. VIVA TRAP: Is routine bone marrow aspiration mandatory prior to initiating second-line thrombopoietin receptor agonist (TPO-RA) therapy in a child with chronic ITP?	YES. Bone marrow evaluation is mandatory before starting TPO-RA or declaring chronic refractory ITP to conclusively rule out bone marrow failure syndromes, myelodysplastic changes, or ALL.
5. VIVA TRAP: Can live viral MMR vaccination be safely administered to a child currently recovering from acute ITP who is off all immunosuppressive therapy?	YES. Once a child has completely recovered from acute ITP and is off all immunosuppressants, live vaccines can be administered, though transient mild thrombocytopenia can rarely recur following MMR.
6. VIVA TRAP: Should splenectomy be considered as a first-line emergency intervention in a 6-year-old child presenting with severe refractory ITP failing initial IVIG and steroids?	NEVER. Splenectomy is strictly a third-line intervention reserved for children older than 5 years with severe chronic refractory ITP lasting greater than 12 months with significant bleeding.
7. VIVA TRAP: Can Eltrombopag be co-administered simultaneously with an oral multivitamin containing calcium, iron, or magnesium to a pediatric patient?	NEVER. Polyvalent cations (calcium, iron, magnesium, aluminum) chelate Eltrombopag in the gastrointestinal tract, drastically reducing its systemic absorption; it must be taken at least 2 hours before or 4 hours after such supplements.
8. VIVA TRAP: Is it acceptable to allow a child with active wet purpura, epistaxis, and a platelet count of 8,000/µL to participate in contact sports like football or wrestling during watchful waiting?	NEVER. Contact sports, rough play, and high-impact physical activities are strictly contraindicated when a child has severe thrombocytopenia with wet purpura due to the high risk of catastrophic intracranial hemorrhage.
9. VIVA TRAP: Can the diagnostic label of primary ITP be maintained if a child with isolated thrombocytopenia is found to have mild asymptomatic hepatosplenomegaly on clinical examination?	NO. The presence of hepatosplenomegaly or significant lymphadenopathy completely excludes primary ITP and mandates immediate investigation for secondary causes such as leukemia, lymphoma, or storage disorders.
10. VIVA TRAP: Is intravenous anti-D immunoglobulin therapy safe to administer to an Rh-positive pediatric ITP patient who has experienced active autoimmune hemolytic anemia?	NEVER. Anti-D immunoglobulin works by inducing deliberate immune-mediated hemolysis of Rh-positive red blood cells by splenic macrophages; administering it to a patient with active hemolysis risks catastrophic worsening.
11. VIVA TRAP: Can subcutaneous or intramuscular injections, blood draws via deep venipuncture, or arterial blood gas sampling be performed routinely without precautions in a child with a platelet count of 12,000/µL?	NEVER. Intramuscular injections and deep arterial punctures are strictly contraindicated in severe thrombocytopenia due to the extreme risk of developing large, compartment-threatening hematomas.
12. VIVA TRAP: Is a repeat diagnostic bone marrow aspiration required every 6 months in a child with uncomplicated chronic ITP who is clinically stable and responding well to TPO-RAs?	NONE. Routine repeat bone marrow aspirations are unnecessary in stable, responding chronic ITP; marrow evaluation is only repeated if atypical clinical features, cytogenetic shifts, or treatment failures emerge.
13. VIVA TRAP: Can aspirin, ibuprofen, or other non-steroidal anti-inflammatory drugs (NSAIDs) be prescribed for mild fever or joint aches in a child diagnosed with acute ITP?	NEVER. NSAIDs and aspirin severely impair platelet aggregation and inhibit cyclooxygenase, which can precipitate catastrophic gastrointestinal or mucosal hemorrhage in a patient with profound thrombocytopenia.
14. VIVA TRAP: Is outpatient management permissible for a newly diagnosed pediatric ITP patient presenting with active wet purpura (epistaxis and oral blood blisters) and a platelet count of 4,000/µL?	NO. Wet purpura and mucosal bleeding indicate high-risk bleeding; such patients require immediate hospital admission, urgent active pharmacotherapy (IVIG or high-dose steroids), and close inpatient hemodynamic monitoring.
15. VIVA TRAP: Can a diagnosis of primary ITP be confirmed solely on the basis of a low platelet count without verifying normal values for hemoglobin and total leukocyte counts on the peripheral smear?	NEVER. Primary ITP is a diagnosis of exclusion defined by isolated thrombocytopenia; normal hemoglobin and leukocyte parameters along with a normal differential count are mandatory to rule out bone marrow failure states.
16. VIVA TRAP: Can a child presenting with dry purpura and a profoundly low platelet count of 5,000/µL be safely evaluated in an outpatient clinic without checking vital signs or performing a detailed abdominal palpation for organomegaly?	NEVER. 1. Baseline vital signs and thorough abdominal examination for hepatosplenomegaly or lymphadenopathy are mandatory to rule out acute leukemia, aplastic anemia, or infiltrative malignancies masquerading as ITP. 2. Omitting a physical examination risks missing life-threatening systemic red flags before declaring a case as isolated primary ITP.
17. VIVA TRAP: Should emergency diagnostic bone marrow examination be performed immediately in every newly presenting toddler with classic acute onset petechiae and ecchymoses following an upper respiratory infection?	NO. 1. International guidelines do not recommend routine bone marrow aspiration in children presenting with typical features of newly diagnosed acute ITP, normal peripheral blood smears, and no atypical systemic findings. 2. Bone marrow examination is strictly reserved for atypical presentations, persistent or chronic courses prior to second-line therapies, or when unexplained cytopenias are identified on the peripheral smear.